E-LIB Suche - Ergebnisse für: Poulin, Y.

1

Position statement for a pragmatic approach to immunotherap..:

Beecker, J. ; Papp, K.A. ; Dutz, J....
Journal of the European Academy of Dermatology and Venereology. 35 (2021) 4 - p. 797-806 , 2021

Link: https://doi.org/10.1111/..

2

Distance of Hi-GAL sources:

Mège, P. ; Russeil, D. ; Zavagno, A....
Astronomy & Astrophysics. 646 (2021) - p. A74 , 2021

Link: https://doi.org/10.1051/..

3

Disease activity and treatment efficacy using patient-level..:

Gordon, K. B. ; Reich, K. ; Crowley, J. J....
Journal of Dermatological Treatment. 33 (2020) 1 - p. 219-228 , 2020

Link: https://doi.org/10.1080/..

4

Certolizumab Pegol for Treatment of Plaque Psoriasis: Poole..:

Gordon, K ; Warren, R B ; Gottlieb, A B...
SKIN The Journal of Cutaneous Medicine. 4 (2020) 5 - p. s44 , 2020

Link: https://doi.org/10.25251..

5

Long‐term efficacy of certolizumab pegol for the treatment ..:

Gordon, K.B. ; Warren, R.B. ; Gottlieb, A.B....
British Journal of Dermatology. 184 (2020) 4 - p. 652-662 , 2020

Link: https://doi.org/10.1111/..

6

Tralokinumab for moderate‐to‐severe atopic dermatitis: resu..:

Wollenberg, A. ; Blauvelt, A. ; Guttman‐Yassky, E....
British Journal of Dermatology. 184 (2020) 3 - p. 437-449 , 2020

Link: https://doi.org/10.1111/..

7

Efficacy of tildrakizumab by patient demographic and diseas..:

Poulin, Y. ; Ramon, M. ; Rosoph, L....
Journal of the European Academy of Dermatology and Venereology. 34 (2020) 7 - p. 1500-1509 , 2020

Link: https://doi.org/10.1111/..

8

Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Ever..:

Gordon, K ; Warren, R B ; Gottlieb, A B...
SKIN The Journal of Cutaneous Medicine. 4 (2020) 5 - p. s45 , 2020

Link: https://doi.org/10.25251..

9

Reductions in Absolute PASI Over 144 Weeks of Treatment wit..:

Gottlieb, AB ; Blauvelt, A ; Thaçi, D...
SKIN The Journal of Cutaneous Medicine. 4 (2020) 6 - p. s84 , 2020

Link: https://doi.org/10.25251..

10

Efficacy and safety of risankizumab vs. secukinumab in pati..:

Warren, R.B. ; Blauvelt, A. ; Poulin, Y....
British Journal of Dermatology. 184 (2020) 1 - p. 50-59 , 2020

Link: https://doi.org/10.1111/..

11

Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Ever..:

Gordon, K ; Warren, RB ; Gottlieb, AB...
SKIN The Journal of Cutaneous Medicine. 4 (2020) 6 - p. s81 , 2020

Link: https://doi.org/10.25251..

12

Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Ev..:

Gordon, K ; Warren, R.B. ; Gottlieb, A.B....
SKIN The Journal of Cutaneous Medicine. 3 (2019) - p. S36 , 2019

Link: https://doi.org/10.25251..

13

Constance de la réponse selon l'âge chez des patients attei..:

Kontantinou, M.P. ; Armstrong, A. ; Poulin, Y....
Annales de Dermatologie et de Vénéréologie. 146 (2019) 12 - p. A335 , 2019

Link: https://doi.org/10.1016/..

14

Étude de phase 2b sur némolizumab chez des patients adultes..:

Bouaziz, J.-D. ; Silverberg, J. ; Pinter, A....
Annales de Dermatologie et de Vénéréologie. 146 (2019) 12 - p. A109 , 2019

Link: https://doi.org/10.1016/..

15

Adalimumab for nail psoriasis: efficacy and safety over 52 ..:

Elewski, B.E. ; Baker, C.S. ; Crowley, J.J....
Journal of the European Academy of Dermatology and Venereology. 33 (2019) 11 - p. 2168-2178 , 2019

Link: https://doi.org/10.1111/..